CN116322768A - 激活素a抗体调配物和其使用方法 - Google Patents

激活素a抗体调配物和其使用方法 Download PDF

Info

Publication number
CN116322768A
CN116322768A CN202180059660.5A CN202180059660A CN116322768A CN 116322768 A CN116322768 A CN 116322768A CN 202180059660 A CN202180059660 A CN 202180059660A CN 116322768 A CN116322768 A CN 116322768A
Authority
CN
China
Prior art keywords
antibody
antigen
binding portion
formulation
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059660.5A
Other languages
English (en)
Chinese (zh)
Inventor
D·卡门
K·格雷厄姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN116322768A publication Critical patent/CN116322768A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202180059660.5A 2020-06-18 2021-06-18 激活素a抗体调配物和其使用方法 Pending CN116322768A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040589P 2020-06-18 2020-06-18
US63/040,589 2020-06-18
PCT/US2021/038016 WO2021257947A1 (en) 2020-06-18 2021-06-18 Activin a antibody formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
CN116322768A true CN116322768A (zh) 2023-06-23

Family

ID=77168377

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059660.5A Pending CN116322768A (zh) 2020-06-18 2021-06-18 激活素a抗体调配物和其使用方法

Country Status (13)

Country Link
US (1) US12472253B2 (https=)
EP (1) EP4168038A1 (https=)
JP (1) JP7850084B2 (https=)
KR (1) KR20230026407A (https=)
CN (1) CN116322768A (https=)
AU (1) AU2021293577A1 (https=)
BR (1) BR112022025700A2 (https=)
CA (1) CA3183316A1 (https=)
CL (1) CL2022003586A1 (https=)
CO (1) CO2023000264A2 (https=)
IL (1) IL299103A (https=)
MX (1) MX2022016403A (https=)
WO (1) WO2021257947A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106648A (zh) * 2014-09-12 2017-08-29 瑞泽恩制药公司 进行性骨化性纤维发育不良的治疗
US20180008672A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2019099838A1 (en) * 2017-11-16 2019-05-23 Novartis Ag Combination therapies
WO2019169283A1 (en) * 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
MA46046A (fr) 2016-08-29 2019-07-03 Regeneron Pharma Anticorps anti-gremlin-1 (grem1) et procédés d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106648A (zh) * 2014-09-12 2017-08-29 瑞泽恩制药公司 进行性骨化性纤维发育不良的治疗
US20180008672A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2019099838A1 (en) * 2017-11-16 2019-05-23 Novartis Ag Combination therapies
WO2019169283A1 (en) * 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANG JICHAO等: "Rapid Formulation Development for Monoclonal Antibodies", 《BIOPROCESS INTERNATIONAL》, vol. 14, no. 4, 30 April 2016 (2016-04-30), pages 40 *

Also Published As

Publication number Publication date
US12472253B2 (en) 2025-11-18
JP7850084B2 (ja) 2026-04-22
CL2022003586A1 (es) 2023-07-21
BR112022025700A2 (pt) 2023-02-28
JP2023532203A (ja) 2023-07-27
CA3183316A1 (en) 2021-12-23
EP4168038A1 (en) 2023-04-26
CO2023000264A2 (es) 2023-01-26
KR20230026407A (ko) 2023-02-24
MX2022016403A (es) 2023-04-11
IL299103A (en) 2023-02-01
WO2021257947A1 (en) 2021-12-23
AU2021293577A1 (en) 2023-02-09
US20210393779A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
US11926670B2 (en) Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
US10752701B2 (en) Stabilized formulations containing anti-PCSK9 antibodies
KR20220131923A (ko) 안정한 항체 제형
TW201400130A (zh) 包含抗－ｄｌｌ４抗體的穩定化調配物
US12472253B2 (en) Activin a antibody formulations and methods of use thereof
EA049032B1 (ru) Составы на основе антитела к a-активину и способы их применения
HK40039744A (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1258305A1 (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1258305B (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1188559A (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1188559B (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination